Truist Securities Maintains Buy on ANI Pharmaceuticals, Raises Price Target to $60
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Gregory Fraser has maintained a 'Buy' rating on ANI Pharmaceuticals (NASDAQ:ANIP) and raised the price target from $52 to $60.
July 21, 2023 | 2:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ANI Pharmaceuticals' price target has been raised from $52 to $60 by Truist Securities, which maintains a 'Buy' rating on the stock.
The raised price target and maintained 'Buy' rating by Truist Securities indicates a positive outlook for ANI Pharmaceuticals. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100